ABSTRACT
OBJECTIVE: This study assesses the mortality outcomes of non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with venous thromboembolism (VTE) and atrial fibrillation (AF). METHODS: Medical records of cancer patients receiving NOACs for VTE or AF between January 1, 2011, and December 31, 2016, were retrieved from Taiwan's National Health Institute Research Database. NOACs were compared using the inverse probability of treatment weighting (IPTW) method. The primary outcome was cancer-related death. Secondary outcomes were all-cause mortality, major bleeding, and gastrointestinal (GI) bleeding. RESULTS: Among 202,754 patients who received anticoagulants, 3591 patients (dabigatran: 907; rivaroxaban: 2684) with active cancers were studied. Patients who received dabigatran were associated with lower risks of cancer-related death at one year (HR = 0.71, 95% CI = 0.54-0.93) and at the end of follow-ups (HR = 0.79, 95% CI = 0.64-0.98) compared with rivaroxaban. Patients who received dabigatran were also associated with lower risks of all-cause mortality (HR = 0.81, 95% CI = 0.67-0.97), major bleeding (HR = 0.64, 95% CI = 0.47-0.88), and GI bleeding (HR = 0.57, 95% CI = 0.39-0.84) at the end of follow-ups compared with rivaroxaban. CONCLUSION: Compared with rivaroxaban, the use of dabigatran may be associated with a lower risk of cancer-related death and all-cause mortality.
Subject(s)
Antithrombins/therapeutic use , Atrial Fibrillation/complications , Dabigatran/therapeutic use , Neoplasms/mortality , Rivaroxaban/therapeutic use , Venous Thromboembolism/prevention & control , Aged , Aged, 80 and over , Antithrombins/adverse effects , Cause of Death , Dabigatran/adverse effects , Female , Gastrointestinal Hemorrhage/chemically induced , Hemorrhage/chemically induced , Humans , Male , Middle Aged , Neoplasms/complications , Rivaroxaban/adverse effects , TaiwanABSTRACT
Peripartum cardiomyopathy (PPCM), often classified as a form of dilated cardiomyopathy (DCM), is the myocardial dysfunction that occurs in late pregnancy and through the first few postpartum months.The aim of this study is to investigate the differences in the clinical outcomes of PPCM and DCM.Electronic medical records from 1997 to 2011 were retrieved from the Taiwan National Health Insurance Research Database. Patients with PPCM were compared with age- and clinical characteristics-matched patients with DCM. Primary outcomes were 1- and 3-year heart failure (HF) readmission, cardiac death, all-cause mortality, and major adverse cardiovascular events. Secondary outcomes were myocardial infarction, new onset of dialysis, heart transplant, and cerebrovascular accident. Follow-up period was divided into "within the first year" and "after the first year."A total of 527,979 patients (253,166 females) were hospitalized with a principal diagnosis of HF during 1997 to 2011 period. After excluding patients aged <18 and >50 years, patients with other forms of HF, and those with a history of cerebrovascular accidents or coronary artery disease, 797 patients with PPCM and 1267 patients with DCM were evaluated. Propensity score matching yielded 391 patients in each group. Patients with DCM had a significantly worse prognosis compared to those with PPCM for all primary and secondary outcomes at the 1- and 3-year follow-ups. After 1 year, the HF readmission rate did not significantly differ between the 2 diseases, suggesting that HF medications should be aggressively instituted in patients with PPCM.This is the first study to directly compare the clinical outcomes between age-matched patients with PPCM and DCM. Patients with PPCM had a significantly better prognosis across all cardiovascular endpoints compared to patients with DCM.
Subject(s)
Cardiomyopathy, Dilated/mortality , Cardiomyopathy, Dilated/therapy , Pregnancy Complications, Cardiovascular/mortality , Pregnancy Complications, Cardiovascular/therapy , Adult , Databases, Factual , Female , Follow-Up Studies , Heart Failure/mortality , Heart Failure/therapy , Humans , Male , Middle Aged , National Health Programs , Patient Readmission/statistics & numerical data , Peripartum Period , Pregnancy , Propensity Score , Taiwan/epidemiology , Treatment Outcome , Young AdultABSTRACT
OBJECTIVE: To investigate the chemical constituents of Lespedeza virgata. METHOD: The constituents were isolated by column chromatography and their structures were elucidated by chemical properties and spectroscopic evideuce. RESULT: Seven components were isolated and identified as quercetin 3-O-[2"-O-( E'-6"-O-feruloyl)-beta-D-glucopyranosyl]-beta-D-galact opyranoside (1), kaempferol-7-O-L-rhamnopyranoside (2), 7-O-alpha-L-rhamnopyransyl-kaempeferol-3-O-beta-D-glucopyranoside (3), quercetine (4), E-beta-hydroxycinnamic acid (5), protocatechuic acid (6), p-hydroxybenzoic (7). CONCLUSION: Seven components are isolated from L. virgata for the first time.